Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug;11(4):629-631.
doi: 10.21037/hbsn-2022-12.

Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air

Vikrant Rai  1 , Sandeep Mukherjee  2
Affiliations
Editorial

Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air

Vikrant Rai et al. Hepatobiliary Surg Nutr. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2022-12/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Combination therapies and proposed strategies to be considered for better clinical outcome. HCC, hepatocellular carcinoma; TKI, tyrosine kinase inhibition; TACE, transarterial chemoembolization; TATI, transarterial chemoembolization, ablation, tyrosine kinase inhibition, immunotherapy; ASCO-NHB, American Society of Clinical Oncology-Net Health Benefit; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TGF-β, transforming growth factor beta; OS, overall survival; HR, hazard ratio; PFS, progression free survival; ORR, objective response rate; TTR, time to response; CR, complete response; PR, partial response.
See this image and copyright information in PMC

Comment on

References

    1. Zhang T, Merle P, Wang H, et al. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10:180-92. 10.21037/hbsn-2021-7 - DOI - PMC - PubMed
    1. Li X, Wang Y, Ye X, et al. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. 10.3389/fmolb.2021.635243 - DOI - PMC - PubMed
    1. Meng M, Li W, Yang X, et al. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. J Cancer Res Ther 2020;16:327-34. 10.4103/jcrt.JCRT_101_20 - DOI - PubMed
    1. Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol 2016;34:2925-34. 10.1200/JCO.2016.68.2518 - DOI - PubMed
    1. Li D, Crook C, Ballena R, et al. Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution? JCO Oncol Pract 2021;17:164-6. 10.1200/OP.20.01018 - DOI - PubMed